Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with Beam and Busulfan/Melphalan (Bu/Mel) in Concurrent Cohorts of Refractory Hodgkin'S Lymphoma (HL) Patients Receiving an Autologous Stem-Cell Transplant
Year: 2012
Type: article
Abstract: BEAM is considered a standard HDC regimen for pts with Hodgkin's lymphoma (HL) who are candidates for an ASCT. However, pts with primary refractory tumors or high-risk relapse have poor outcomes after BEAM, underscoring the need for more active HDC combinations.
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W1971219027